Increased ADAMTS13 activity in patients with venous thromboembolism

Mazetto, Bruna de Moraes; Orsi, Fernanda Andrade; Barnabé, Aline; Paula, Erich Vinícius De; Flores-Nascimento, Mariane Cristina; Annichino‐Bizzacchi, Joyce Maria

doi:10.1016/j.thromres.2012.09.009

Cited by 28 publications

(35 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cancer patients have been shown to have higher VWF levels and lower ADAMTS‐13 levels than the general population, often also in a stage‐dependent intensity …”

Section: Introductionmentioning

confidence: 99%

“…In a recent study VWF and ADAMTS‐13 were shown to be associated with occurrence of VTE in cancer patients, with ADAMTS‐13 exhibiting predictive potential in risk scores . Patients with VTE or history of VTE have been repeatedly shown to have higher mean levels of VWF, however, patients with underlying malignancy have always been excluded. Data on ADAMTS‐13 and its association with VTE, on the other hand, is ambiguous.…”

Section: Introductionmentioning

confidence: 99%

“…Data on ADAMTS‐13 and its association with VTE, on the other hand, is ambiguous. There are studies showing decreased or increased ADAMTS‐13 activity with venous thrombosis. With next‐generation sequencing, one scientific group found an excess of rare coding single‐nucleotide variants of the ADAMTS‐13 gene in patients with deep vein thrombosis (DVT) while another group failed to find a link between DVT and a polymorphism associated with reduced levels of ADAMTS‐13 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

Obermeier

Riedl

et al. 2019

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Cancer is associated with increased risk of developing venous thrombosis. Cancer patients were studied for ADAMTS‐13 and VWF levels and occurrence of venous thrombosis. Increased VWF in cancer patients is associated with a higher risk of venous thrombosis. Low levels of ADAMTS‐13 and/or increased VWF in cancer patients are associated with worse survival. Background Cancer‐associated venous thromboembolism (VTE) is an important complication in the course of a malignant disease. Low ADAMTS‐13 (a disintegrin‐like and metalloproteinase with thrombospondin type 1 motif 13) and increased von Willebrand Factor (VWF) levels in cancer patients have been described numerously. Objectives Investigation of the influence of ADAMTS‐13 and VWF on the probability of VTE and survival in malignancy. Patients/Methods In the framework of the ongoing prospective Cancer and Thrombosis Study (CATS) ADAMTS‐13 activity and VWF antigen levels were investigated in cancer patients. Results In total, 795 patients with various tumor types (364 female/431 male, median age 62 years) were included; of those, 56 developed VTE and 359 patients died during a median follow‐up time of 730 days. The hazard ratio (HR) of VTE per doubling of VWF level was 1.56 (95% confidence interval [CI] 1.13‐2.16) in multivariable competing risk analysis. ADAMTS‐13 levels showed no correlation with the incidence of VTE in univariate competing risk analysis. The HR of mortality per doubling of VWF level was 1.46 (95% CI 1.28‐1.66) and per SD increment of ADAMTS‐13was 0.90 (95% CI 0.81‐1.00) in multivariable Cox regression analysis. Patients with VWF >75th percentile and concomitant low (<25th percentile) or medium (25‐75th percentile) ADAMTS‐13 values had the highest probability of mortality (HR 4.31 and 4.75, respectively). Conclusions High VWF levels were significantly associated with the risk of developing VTE in cancer patients, whereas ADAMTS‐13 was not. Low ADAMTS‐13 and increased VWF levels were independently associated with worse overall survival.

show abstract

“…Cancer patients have been shown to have higher VWF levels and lower ADAMTS‐13 levels than the general population, often also in a stage‐dependent intensity …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

Obermeier

Riedl

et al. 2019

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and IL-8, are considerably elevated in patients with residual vein occlusion (RVO) with high levels of D-dimer (months to years after occurrence of VTE) compared to patients without RVO with normal levels of D-dimer and controls without VTE [20,21]. Regardless of the levels of D-dimer, VTE patients have higher levels of TNF-α and IL-6 than controls without VTE, even after discontinuation of anti-coagulant therapy [21,22]. In baboons, DVT can be induced by injection of antibody to protein C, TNF, stasis and venous catheter injury, which results in elevation of the levels of proinflammatory cytokines, e.g., TNF-α, IL-6, and IL-8 [23].…”

Section: Proinflammatory Cytokinesmentioning

confidence: 99%

Inflammation in venous thromboembolism: Cause or consequence?

Saghazadeh

Hafizi

Rezaei

2015

International Immunopharmacology

111

View full text Add to dashboard Cite

“…The reasons for PTS development are poorly understood and association with inflammatory response and residual vein thrombosis (RVT) has been considered controversial [8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Severe postthrombotic syndrome is associated with characteristic sonographic pattern of the residual thrombosis

Mazetto

Orsi²,

Silveira³

et al. 2016

Blood Coagulation &Amp; Fibrinolysis

Self Cite

View full text Add to dashboard Cite

Postthrombotic syndrome (PTS) may affect 50% of patients with deep venous thrombosis, 5-10% of them may present severe manifestations. The causes for PTS development and severity have not been well established. This study evaluated whether PTS may be associated with the presence, and echogenicity, of the residual vein thrombosis (RVT). We included patients with a history of deep venous thrombosis in the past 58 months. These patients were further evaluated for PTS diagnosis, clinical comorbidities, plasma levels of D-dimer, serum levels of C-reactive protein and for the presence of RVT. Particularly, RVT was detected by ultrasound examination and the residual thrombi echogenicity was determined by grayscale median (GSM). Fifty-six patients were included, of which 41 presented PTS. Mild PTS was detected in 23 patients, moderate PTS in 11 and severe PTS in seven patients. Patients with severe PTS showed higher body mass index, higher abdominal circumference and higher C-reactive protein levels when compared with the other patients (P = 0.007, P = 0.002, P = 0.02, respectively). The ultrasound-generated GSM was significantly lower in patients with severe PTS compared with patients with mild-moderate PTS or no PTS (median = 24, 35 and 41, respectively; P = 0.04). A GSM value less than 25, which was consistent with a hypoechoic RVT, was the best cut-off value to discriminate patients with severe PTS from those with mild or moderate PTS and those without PTS. RVT is a common finding among patients with PTS and the echogenicity of the RVT may impact the severity of PTS.

show abstract

Increased ADAMTS13 activity in patients with venous thromboembolism

Cited by 28 publications

References 28 publications

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

Inflammation in venous thromboembolism: Cause or consequence?

Severe postthrombotic syndrome is associated with characteristic sonographic pattern of the residual thrombosis

Contact Info

Product

Resources

About